Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.
Also called NCT01970501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 267 participants
- Sponsor
- Registry
-
NCT01970501
-
- Other papers using this trial's data
- Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Hungary, Netherlands, Poland, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT01970501. Randomized; quadruple masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2017-12-28 (actual). Results posted on 2022-09-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
- Acronym
- GENETIC-AF
- Condition
- Current or Recent History of Atrial Fibrillation
- Intervention (Drug)
- bucindolol hydrochloride
- Intervention (Drug)
- metoprolol succinate
- Intervention (Other)
- Placebo oral capsule
- Lead sponsor
- ARCA Biopharma, Inc.
- Collaborator
- Medtronic
Record details
- Record id
cardio:ct-nct01970501- Content hash
d943c71a81c962078c01e9ee2a1ccdd32e9580ce0d8f506b566cc3dcb50ad886